Emerging bedaquiline-resistant tuberculosis
Christoph Lange, Anca Vasiliù, Anna M. Mandalakas
Abstract
Tuberculosis is the leading cause of death attributed to a single infectious pathogen worldwide. Despite the availability of anti-tuberculosis therapies for more than half a century, the number of people affected by tuberculosis reached a historical peak in 2021.1 In the absence of a vaccine that is substantially more effective than the Mycobacterium bovis bacilli Calmette Guérin vaccine, the elimination of tuberculosis is highly unlikely anytime soon. Over the past decade, a substantial increase in the number of individuals identified with multidrug-resistant or rifampicin-resistant tuberculosis has been observed.
Topics & Concepts
TuberculosisBedaquilineMycobacterium tuberculosisMycobacterium bovisRifampicinMedicineVirologyPathogenBCG vaccineInfectious disease (medical specialty)MicrobiologyImmunologyDiseaseBiologyInternal medicinePathologyTuberculosis Research and EpidemiologyPneumonia and Respiratory InfectionsPneumocystis jirovecii pneumonia detection and treatment